79.10 +2.85 (3.74%)
Pre-market: 7:42AM EDT
|Bid||77.98 x 1200|
|Ask||79.16 x 800|
|Day's range||75.32 - 77.44|
|52-week range||65.25 - 92.64|
|Beta (5Y monthly)||0.69|
|PE ratio (TTM)||20.01|
|Forward dividend & yield||2.44 (3.17%)|
|Ex-dividend date||12 Mar 2020|
|1y target est||N/A|
Drugs and chemicals maker Merck KGaA on Monday became the second German blue-chip company to move its annual shareholders' meeting online after the government laid the ground for such a switch last week. "Merck will seize the opportunity created by legislators to hold the 2020 annual general meeting in a virtual format - not least to allow for a payout to shareholders of the dividend that was proposed for the 2019 business year as soon as possible," a spokesman told Reuters. Merck earlier this month proposed https://www.merckgroup.com/investors/reports-and-financials/earnings-materials/2019-q4/en/2019-Q4-Press-Release-EN.pdf a dividend of 1.30 euros ($1.44) per share.
Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels predicts the most vulnerable will begin to receive vaccines within 12 months to prevent COVID-19.
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
AstraZeneca (AZN)/Merck's (MRK) study evaluating cediranib added to Lynparza fails to meet the primary endpoint of PFS in patients with platinum-sensitive relapsed ovarian cancer
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Merck KGaA said core earnings would see "strong" growth in 2020 when adjusted for one-offs and currency swings, but it would have to revise goals if the coronavirus outbreak does not start to ease from next month. "Should the crisis grow or trigger a global recession, the company would adapt its business forecast," it said in a statement.
(Bloomberg) -- Palantir Technologies Inc. scored another win in Washington Tuesday, securing a contract worth as much as $823 million to provide software to the Department of Defense, according to communications reviewed by Bloomberg.The four-year deal represents more than a decade of work by the Palo Alto, California-based data mining startup to break into the club of existing defense contractors, and bolsters the company’s prospects as it prepares it to go public.The contract is the second half of a larger project. Palantir and Raytheon Co. won the first half of the deal in 2018, worth $876 million. This second part involves Palantir working with BAE Systems to replace the U.S. Army’s Distributed Common Ground System, used for aggregating and analyzing data, which has faced technical challenges. Palantir sued the Army in 2016 to win the right to compete for the new contract after the U.S. Government Accountability Office determined the old system was underperforming and over budget. It is unclear how revenue from the contract will be split between Palantir and BAE Systems. The deal will increase annual sales at Palantir’s government division from its current $500 million or so, according to people familiar with Palantir’s finances who asked not to be identified discussing private information. Investor Peter Thiel co-founded Palantir in 2004, and the company’s software has been used for controversial ends like enabling the immigration deportation policies championed by President Trump, as well as for philanthropic ones like preventing sex trafficking and finding missing children.About half of Palantir’s business relies on deals with large corporate customers like Merck KGaA and Airbus SE, which use the software to manage drug discovery and improve supply chain logistics.The company is exploring both an IPO and a direct listing, but does not yet have a target date for going public, Bloomberg has reported. To contact the author of this story: Lizette Chapman in San Francisco at firstname.lastname@example.orgTo contact the editor responsible for this story: Anne VanderMey at email@example.com, Alistair BarrFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
The yearly results for Merck & Co., Inc. (NYSE:MRK) were released last week, making it a good time to revisit its...
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
U.S. stocks rallied for a third straight day on Wednesday on encouraging U.S. economic data and waning fears of the financial fallout from a virus out of China but losses in Tesla shares pulled the Nasdaq off its record high. The ADP National Employment Report showed private payrolls jumped by 291,000 jobs in January, the most since May 2015, while a separate report showed U.S. services sector activity picked up in January, suggesting the economy could continue to grow moderately this year even as consumer spending is slowing. "There is at least not as much of a fear of an outcome of a pandemic that will have as much economic pressure globally as maybe initially was thought,” said Delores Rubin, senior equities trader at Deutsche Bank Wealth Management in New York.
Monthly private-sector payrolls from Automatic Data Processing (ADP) for January posted their highest level this morning since May 2015, to a whopping 291K new private-sector jobs having been created.
Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.
Investing.com - Merck&Co; reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.